Duke Street Bio Ltd. has divulged poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Scientists at St. John’s University, The University of Pennsylvania and Université de Montréal have identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a cell’s ability to repair DNA damage. Four PARPis are currently approved for use in the ...

[48–50] Final data remain to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed ...

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...

In 2005, researchers in the U.K. struck upon a new way to kill cancer cells. A London-based team led by Alan Ashworth, currently head of the University of California, San Francisco’s cancer center, ...

1). The study reported clinical responses and ... and tolerability profile could differentiate IDX-1197 from other PARP inhibitors. The results informed the design of an ongoing phase 1b/2a ...

Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...

AbbVie’s hopes of getting a so-called PARP inhibitor cancer drug to market are fading after its veliparib failed in two late-stage studies. AstraZeneca’s Lynparza (olaparib) is becoming well ...

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

The objective response rate was 48.8% with a median progression-free survival of 9.1 months. The drug had ... reduction rate compared to approved PARP inhibitors may allow patients to remain ...